Cart
sales@molnova.com
Duvelisib (R enantiomer)
CAS No. 1261590-48-0
Duvelisib (R enantiomer)( IPI-145 R enantiomer | INK1197 R enantiomer | Duvelisib R enantiomer )
Catalog No. M26184 CAS No. 1261590-48-0
Duvelisib R enantiomer is an enantiomer of Duvelisib with lower activity. Duvelisib is a PI3K inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 104 | Get Quote |
|
| 50MG | 325 | Get Quote |
|
| 100MG | 554 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameDuvelisib (R enantiomer)
-
NoteResearch use only, not for human use.
-
Brief DescriptionDuvelisib R enantiomer is an enantiomer of Duvelisib with lower activity. Duvelisib is a PI3K inhibitor.
-
DescriptionDuvelisib R enantiomer is an enantiomer of Duvelisib with lower activity. Duvelisib is a PI3K inhibitor.
-
In Vitro——
-
In Vivo——
-
SynonymsIPI-145 R enantiomer | INK1197 R enantiomer | Duvelisib R enantiomer
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1261590-48-0
-
Formula Weight416.87
-
Molecular FormulaC22H17ClN6O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (239.89 mM)
-
SMILESC[C@@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Wang G, Becker E, Mesa C. Optimization of 6-carboxy-X-rhodamine concentration for real-time polymerase chain reaction using molecular beacon chemistry. Can J Microbiol. 2007 Mar;53(3):391-7.
molnova catalog
related products
-
iMDK
iMDK quarterhydrate is a potent PI3K inhibitor that inhibits the growth factor MDK (also known as midkine or MK). iMDK quarterhydrate synergistically inhibits non-small cell lung cancer (NSCLC) with MEK inhibitors without harming normal cells and mice.
-
GSK-2636771
GSK2636771 is a potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines. Phase 1/2a.
-
Omipalisib
A highly potent dual inhibitor PI3K/mTOR inhibitor.
